Sutro Biopharma
STRO
117 hedge funds and large institutions have $398M invested in Sutro Biopharma in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 56 increasing their positions, 28 reducing their positions, and 10 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 28
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
42% more capital invested
Capital invested by funds: $280M → $398M (+$119M)
4% more funds holding
Funds holding: 113 → 117 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.08% less ownership
Funds ownership: 9.66% → 8.58% (-1.1%)
37% less call options, than puts
Call options by funds: $714K | Put options by funds: $1.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$12.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.11M |
| 3 |
BlackRock
New York
|
+$5.92M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.13M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$3.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$15M |
| 2 |
Millennium Management
New York
|
-$8.12M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.02M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$6.61M |
| 5 |
Holocene Advisors
New York
|
-$3.42M |
STRO Hedge Fund Activity: Q4 2022 in Review
117 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2022, worth a combined $398M — up 42% from $280M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new STRO positions and 10 closed out — a net gain of 8 holders — while 56 added to existing stakes and 28 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $12.6M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $15M sold.
- 117 institutional investors held Sutro Biopharma (STRO) as of Q4 2022, up from 113 in Q3 2022.
- Funds reported $398M of Sutro Biopharma stock for Q4 2022, up 42% quarter-over-quarter.
- 18 funds opened new Sutro Biopharma positions in Q4 2022 and 10 closed out, a net change of +8 holders.
- The largest Sutro Biopharma buyer in Q4 2022 was Rubric Capital Management (New York), an estimated $12.6M added.
- The largest Sutro Biopharma seller in Q4 2022 was Eventide Asset Management, an estimated $15M sold.
Based on aggregated 13F filings for Q4 2022.